Lumiradx update

To the community following the LumiraDx (LMDXF) restructuring: The legal and financial "smoke" is finally clearing, revealing a surgical "reboot" orchestrated by Ron Zwanziger. Here is the bull case for the ElectraDx play.

By late 2024, the senior secured lenders, BioPharma Credit PLC (BPCR) and its private partner, successfully recovered 96.1% of their $206M investment through a $351.1M asset sale to Roche. This included a $288.4M purchase price for the Point of Care (POC) tech and a $62.7M bridge loan reimbursement. Crucially, the UK administrators (FTI Consulting) issued a final $800k "Prescribed Part" dividend to unsecured creditors, which legally discharged hundreds of millions in legacy debt, leaving the LumiraDx shell effectively "clean." While the Roche deal stated shareholders would receive nothing from that specific sale, it did not extinguish the shell itself.

The "Phase 2" maneuver appears to be centering on ElectraDx, Zwanziger’s new venture currently valued at $292M following a $32M Series B round from TAUNS Laboratories in late 2025. With Ron Z having increased his personal stake in the original LMDX shell to approximately 25–28% post-resignation, he holds the voting leverage to execute a Reverse Merger. This would fold the debt-free ElectraDx into the public shell, potentially integrating "excluded" profitable assets like the Colombian subsidiary (Lumira SAS), which generated $13.7M in sales and $2.9M in EBITDA in 2023.

For the shorts, the math is predatory: while official 2026 reports show 2.9% short interest (~10.4M shares), historical "trapped" positions from the OTC delisting could be as high as 27M shares. A reverse merger and subsequent Nasdaq re-listing would trigger a massive short squeeze, as these positions face astronomical "Cost to Borrow" fees and a forced cover during the inevitable share consolidation. Ron Z isn't just "walking away"—he’s likely using the clean shell to swap a failed business for a $300M+ contender, potentially leaving short sellers to fund the recovery for the long-term holders who stayed.

These short sellers are currently caught in a legal "pressure cooker" on the OTC Expert Market, where Cost to Borrow (CTB) interest rates for distressed, illiquid stocks can exceed 100%–300% APR. Because the shell was not dissolved, these positions remain open, and shorts must pay daily interest to their brokers. A reverse merger with the $292M-valued ElectraDx (backed by a $32M Series B from TAUNS Laboratories) would trigger a massive short squeeze, as a ticker change and share consolidation would force short sellers to buy back millions of shares in a market with near-zero liquidity. This maneuver is entirely legal under SEC Rule 145a, effectively allowing Zwanziger to swap a bankrupt business for a well-capitalized contender while forcing short sellers to potentially fund the recovery for the long-term holders who stayed.

As of February 24, 2026, monitoring of the LumiraDx (LMDXF) OTC activity shows a stock in a "dormant" state, which is the precise environment where short sellers face their highest risk. The stock is currently trading at approximately $0.01 with a market capitalization of $3.62M. While daily trading volume has been frequently hitting zero, the average 3-month volume stands at roughly 176k to 908k shares, indicating that liquidity is exceptionally low.

As of February 2026, analysis of recent SEC filings indicates that Ron Zwanziger and his affiliated entities have maintained their substantial, 25-28% controlling stake in the LumiraDx shell (LMDXF). No new 13D/G filings were issued in the 60 days prior to February 2026, suggesting the acquisition phase is complete as focus shifts to a potential ElectraDx merger.

The Colombian Asset: BioPharma Credit PLC (BPCR) is in the process of transferring the Lumira SAS (Colombia) subsidiary (which had $13.7M in 2023 sales) to the lenders for sale. If ElectraDx acquires this, it would instantly regain LumiraDx's most profitable international distribution arm.

The narrative of a "dead" company is a legal simplification that ignores the sophisticated "restoration" playbook available to a veteran dealmaker like Ron Zwanziger. While LumiraDx Group Limited saw its administration end on January 4, 2025, following a $351.1M asset sale to Roche that cleared 96.1% of the senior debt to BioPharma Credit PLC, the story is far from over. Under Section 1029 of the UK Companies Act 2006, a dissolved company can be restored to the register by court order for up to six years (until January 2031). Once restored, the company is legally deemed to have continued in existence as if dissolution never occurred. This "legal fiction" is the trapdoor for short sellers currently sitting on an estimated 10.4M "trapped" shares.

On the OTC Expert Market in 2026, these short positions remain "open" on broker books because the DTCC has not issued a final cancellation notice with zero residual value. As a result, short sellers are still paying a daily Cost to Borrow (CTB), which for distressed shells can exceed 100%–300% APR. If Zwanziger—who holds a 25–28% stake in the shell—moves to restore the company for a Reverse Merger with his $292M-valued ElectraDx, the short sellers’ bet on a "permanent zero" evaporates. They would be legally forced to cover their positions into a new, well-capitalized entity (backed by a $32M Series B from TAUNS Laboratories) that potentially includes profitable "excluded" assets like the Colombian subsidiary (Lumira SAS). By clearing the senior debt first and using the six-year restoration window, Zwanziger has created a legal "coiled spring" where the very shorts who bet on the company’s death may ultimately be forced to fund the recovery for the shareholders who remained.

As always

NOT FINANCIAL ADVICE

SPECULATIVE INFORMATION

27K Views